### Highlights of This Issue 6393

#### SPECIAL FEATURES

**CCR Translations**

6395  
Assessing Iron Overload: Are We There Yet?  
Paul C. Kruger, Michael F. Leahy, and John K. Olynyk  
*See article p. 6460*

6398  
Improving Publication Rates of Biomarker Results from Cancer Trials  
Robert Iannone  
*See article p. 6478*

**Molecular Pathways**

6400  
Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement  
Benjamin H. Lok and Simon N. Powell

**Review**

6407  
p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis  
Steven Habbous, Vincent Pang, Lawson Eng, Wei Xu, Goldie Kurtz, Fei-Fei Liu, Helen Mackay, Eitan Amir, and Geoffrey Liu

**HUMAN CANCER BIOLOGY**

6416  
Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9  
Mei-Hsuan Lu, Chao-Cheng Huang, Mei-Ren Pan, Hong-Hwa Chen, and Wen-Chun Hung

6426  
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping  
Julia D. Waltkühle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Mariana Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhor, Heinz Höller, Laura Eserman on behalf of the I-SPY 1 TRIAL Investigators, Lance A. L iota, Karl-Friedrich Becker, and Emanuel F. Petricoin III

6436  
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies  
Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, and Eduardo Davila

6446  
Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma  
Martin K. Hunn, Kathryn J. Farrand, Kate W.R. Broadley, Robert Weinkove, Peter Fergusson, Rose J. Miller, Cameron S. Field, Troels Petersen, Melanie J. McConnell, and Ian F. Hermans

#### CANCER THERAPY: PRECLINICAL

6460  
MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation  
Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, Malte von Bonin, Claudia Schönfeldt, Sabine Mair, Verena Plodeck, Michael Laniado, Günter Weiss, Johannes Schettig, Gerhard Ehninger, Igor Theurl, Martin Bornhauser, and Uwe Platzerbecker  
*See commentary p. 6395*

6469  
Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging  
Thomas Nielsen, Lise Bentzen, Michael Pedersen, Trine Tramm, Paul F.J.W. Rijken, Johan Bussink, Michael R. Horsman, and Leif Østergaard
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Stanley B. Kaye, Louis Fehrenbacher, Robert Holloway, Amnon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L. Tauch, Ilsung Chang, and Josina C. Reddy

Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Yunfeng Cui, Jacqueline A. Brosnan, Amanda L. Blackford, Sarojit Sur, Ralph H. Hruban, Kenneth W. Kinzler, Bert Vogelstein, Anirban Maitra, Luis A. Diaz Jr, Christine A. Iacobuzio-Donahue, and James R. Eshleman

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

ACKNOWLEDGMENT TO REVIEWERS

ABOUT THE COVER

Expression of GFP-tagged PROX1 in colon cancer cells reduced E-cadherin and induced epithelial–mesenchymal transition. We found that PROX1 activated miR-9 expression to attenuate E-cadherin protein posttranscriptionally. Results of this study provide a molecular basis by which PROX1 promotes tumorigenesis of colon cancer. For details, see the article by Lu and colleagues on page 6416 of this issue.